Technology Overview

This platform provides a precision screening system for allogeneic MSCs, using single-molecule recognition technology to eliminate low-quality cells and rapidly select high-potency cells for over 40 therapeutic indications. The screening technology integrates molecular biomarkers with activity assays, enabling for a comprehensive analysis of cell efficacy and quality at an early stage. In compliance with TFDA regulations, we established a clinical-grade master cell bank of MSCs. We use a ready-to-use cryopreservation technique that guarantees high cell viability and activity. By integrating key quality control technologies, the complex cell culture process is streamlined into a core industrial technique, significantly simplifying the preparatory work for cell therapy.

Technical Superiority

1. Commercial-scale production – Cells from a single donor can produce 100,000–500,000 therapeutic doses

2. Lower cost and risk – Estimated treatment cost is only one-tenth of current cell therapies with reduced contamination risk

3. On-demand supply – Ready-to-use with stable and reliable availability

4. Improved clinical outcomes – Helps increase survival rates and post-treatment quality of life for critical and acute patients

Application

1. Novel clinical cell screening platform service

2. Applications in regenerative medicine and cell therapy

3. Two application products — allogeneic MSC therapy for acute myocardial infarction and allogeneic MSC therapy for diabetic foot ulcers — have been approved by TFDA and licensed to domestic biopharmaceutical companies for clinical trials